Medical weight loss is a physician-supervised approach that may include GLP-1 class medication alongside nutrition and activity support. The evidence supports reduced appetite and gradual weight loss over about a year, with wide individual variation; it suits only patients who meet eligibility criteria, and weight tends to return after stopping without ongoing support.
Medical weight loss has shifted considerably over the past five years. The arrival of GLP-1 class medications has given physicians a reliable pharmacological lever for sustained weight reduction. This article unpacks how these therapies work, what the published evidence actually shows, and how candidate evaluation should be done at a physician-led clinic. This is an information-layer article. It is not a substitute for the personalised assessment that takes place during a consultation with Dr. Charles Jiang at Richmond Anti-Aging Clinic (RAAC) in Richmond, BC, Canada. For program details and pricing, visit our medical weight loss service page.
How do GLP-1 medications help with weight loss?
GLP-1 class medications are thought to help mainly in three ways: they reduce appetite signalling in the brain, slow how quickly the stomach empties, and improve insulin sensitivity, so a given meal tends to feel more filling.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the ileum and colon in response to nutrient intake. Endogenous GLP-1 has a half-life of just a few minutes — it is rapidly degraded by dipeptidyl peptidase-4 (DPP-4). Pharmaceutical analogues are engineered to resist this degradation, extending receptor activity from minutes to days. The weight-relevant actions occur on at least three fronts:
- Central appetite suppression. GLP-1 receptors are expressed in the arcuate nucleus and brainstem nuclei that regulate satiety. Activation reduces hunger signalling and increases meal-end satisfaction. Functional MRI studies have shown reduced reward-system activation in response to food cues.
- Delayed gastric emptying. Stomach contents pass into the small intestine more slowly, prolonging the sensation of fullness from a given meal volume.
- Improved insulin sensitivity and glycemic control. GLP-1 enhances glucose-dependent insulin secretion and suppresses glucagon, which is why these drugs were first used for type 2 diabetes before their weight indication. Some agents in this class act on a second incretin pathway (GIP) in addition to GLP-1.
What does the published evidence show about GLP-1 weight loss?
In plain terms, trials support reduced appetite, gradual weight loss over roughly a year rather than weeks, and improving cardiometabolic markers, although individual response varies widely.
The clinical literature on this drug class is unusually mature, and it is the reason physicians treat obesity pharmacologically at all rather than repeating lifestyle advice that has already failed. What the trials support, in plain terms: appetite and food preoccupation fall, weight comes down gradually over roughly a year rather than in weeks, and cardiometabolic markers move in the right direction alongside the weight. Individual response varies widely, and part of a physician's job is to reset expectations before you start. We do not publish specific figures, product names, or dosing here — which medication is appropriate, at what dose, and for how long is a prescribing decision made after an assessment, not something to shop for online.
How does GLP-1 therapy compare with lifestyle change, surgery and body contouring?
GLP-1 therapy sits between lifestyle change alone, which is often insufficient for established obesity, and bariatric surgery for severe obesity; body-contouring devices such as CoolSculpting are not weight-loss tools at all.
It is worth situating GLP-1 therapy among other tools, because the patient question is rarely "should I be on one of these medications?" — it is "what is the right approach for my body?" - Behavioural intervention alone produces modest average weight loss. Effective for some, insufficient for most adults with established obesity.
- Bariatric surgery is the standard guideline option for severe obesity (BMI ≥40) but carries operative risk and irreversible anatomic change.
- Body-contouring procedures (CoolSculpting, EMSculpt) are not weight-loss tools. They work on localised areas — subcutaneous fat (CoolSculpting) or muscle (EMSculpt) — in patients who are already lean. They do not move the BMI needle and are inappropriate as a substitute for medical weight management. A candid clinic conversation matches mechanism to goal. GLP-1 therapy is for systemic weight loss; device-based contouring is for stubborn local fat after weight is stabilised.
Who is a good candidate for GLP-1 weight loss treatment?
Eligibility is usually based on BMI (30 or more, or 27 or more with a weight-related condition), the absence of contraindications, willingness to pair medication with nutrition and activity, and realistic expectations.
Not every patient is a good candidate for GLP-1 therapy. Standard medical eligibility criteria include:
- BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea).
- Absence of contraindications: personal or family history of medullary thyroid carcinoma or MEN2 syndrome, prior pancreatitis, severe gastroparesis.
- Capacity for sustained engagement: pharmacotherapy is most effective alongside nutritional support and physical activity. Patients who plan to use medication as a sole strategy tend to regain weight after discontinuation.
- Realistic expectations about pace (gradual), magnitude (meaningful but not transformative), and duration (likely chronic management, like a blood-pressure medication). At RAAC, this evaluation is conducted by Dr. Charles Jiang (licensed physician in British Columbia, 29+ years of clinical experience). It includes a metabolic panel, weight history, medication review, and goal-setting conversation. Patients with red flags are referred to endocrinology or bariatric services rather than enrolled in our program.
What are the side effects and limitations of GLP-1 treatment?
The main limitations are gastrointestinal side effects while the dose is increased, some loss of muscle along with fat, gradual weight regain after stopping, and the need to know where your medication is sourced.
A responsible discussion includes the known limitations:
- Gastrointestinal side effects (nausea, constipation, occasional vomiting) are common during dose escalation. They are usually transient and managed with slow titration. A small minority discontinue therapy for tolerability.
- Muscle mass loss. A portion of total weight reduction is lean tissue. Resistance training and adequate protein intake during the active loss phase are not optional — they are part of a competent program.
- Weight regain after discontinuation. Trial extension data show that stopping the drug is followed by gradual regain. This is consistent with how the body defends against weight loss generally; it is not a failure of the medication.
- Compounded versus pharmacy-dispensed product quality. Patients should ask where their medication is sourced. Compounded preparations do not carry the same regulatory oversight as a product dispensed through a licensed Canadian pharmacy.
Frequently Asked Questions
How long does a typical program last? Clinical guidelines treat obesity as a chronic condition. Some patients use medication for a defined period to reach a target weight and then transition to a maintenance phase; the length is set by the physician, not by a package. Others continue indefinitely. The decision is individualised. Can I just lose weight with diet and exercise? For some people, yes. For adults with established obesity, the average response to lifestyle intervention alone is meaningful but often insufficient. Medication in this class is intended for patients who have not achieved an adequate response with lifestyle measures alone and who meet eligibility criteria. Is this covered by BC MSP? GLP-1 agonists for weight management are generally not covered by provincial plans for the obesity indication. Some private insurance plans provide partial coverage. Contact us for current pricing. Will I keep the weight off after stopping? Long-term cohort data suggest gradual regain is typical without continued behavioural support. Programs that pair pharmacotherapy with nutritional and activity support produce better maintenance outcomes than medication alone. What about other tools like CoolSculpting? Local fat reduction technologies are not weight-loss tools. They are appropriate after weight is stabilised, for residual stubborn deposits, and only in patients near their target weight.
Why Choose RAAC for Medical Weight Loss
Richmond Anti-Aging Clinic is a physician-led clinic in Richmond, British Columbia, Canada (not Richmond, Virginia). Dr. Charles Jiang is a licensed physician with over 29 years of clinical experience. Programs include a baseline metabolic assessment, individualised dosing under physician supervision, monthly check-ins, and integrated lifestyle coaching. Bilingual care is available in English and Mandarin. Book a consultation to determine whether you are a candidate.
Next Steps
If you are weighing your options, the most useful next step is a one-on-one assessment rather than further reading. Bring your medical history, current medications, and a sense of what "success" would look like for you. Schedule your consultation today — we will give you an honest read on fit, expected magnitude of response, and program structure.
This article is for educational purposes only and does not constitute medical advice. Please consult with a qualified healthcare professional before undergoing any treatment.
